Our laboratory is uniquely positioned within the Myeloma Service at the Department of Medicine at UM/SCCC, a world leader in early drug development and cancer research, providing state-of-the art care for multiple myeloma patients across the United States and internationally. This ensures access to patient samples and clinical data derived from the use of cutting-edge therapies. Together with a strong network of collaborators, we are currently interrogating large datasets of whole genome, exome, RNA sequencing, and single-cell technologies to determine the impact of mutational signatures, structural variants, and rare drivers on multiple myeloma pathogenesis and clinical outcome after novel therapies.